# **Dental Extractions in Patients Prior to Stem Cell Transplantation**

Fernanda Cristina Melo Pelinsari<sup>1</sup>,Bruna Mara Ruas<sup>1</sup>, Thais dos Santos Fontes Pereira<sup>1</sup>, Renata Gonçalves Resende<sup>2</sup>, Aécio Abner Campos-Pinto Jr<sup>1</sup>, Maria Elisa de Souza e Silva<sup>2</sup>, Ricardo Santiago Gomez<sup>1</sup>

<sup>1</sup>Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. <sup>2</sup>Stomatology service, Odilon Behrens Hospital, Belo Horizonte, Minas Gerais, Brazil. <sup>3</sup>Departament of Restorative Dentistry, School of Dentistry, Belo Horizonte, Minas Gerais, Brazil.

## **Abstract**

The purpose of the study was to evaluate the incidence of complications of dental surgical procedures conducted in patients requiring hematopoietic stem cell transplantation (HSCT). This retrospective cohort study included 33 patients with hematologic diseases in need of dental extraction. The variables evaluated were age, gender, primary disease, platelet count, number of extracted teeth, leukocyte count, and hemoglobin and hematocrit levels. Seven patients showed platelet count below  $100,000/\mu L$ . None of the patients presented any significant bleeding during or after the surgical procedures. Also, no infectious complications were observed. In conclusion, bleeding complications are rare in patients with hematological conditions requiring HSCT and dental extraction procedures are safe.

Key Words: Dental extraction, Hematopoietic stem cell transplantation, Oral surgery, Bleeding

## Introduction

Management of thrombocytopenic patients in need of Hematopoietic Stem Cell Transplantation (HSCT) is a challenge for dentists as it involves meticulous preoperative planning, while taking into consideration the patient's medical condition, his/her systemic debilities, and the imminent risk of complications such as bleeding. HSCT is indicated as a therapeutic measure for hematological malignancies, bone marrow deficiencies or other congenital disorders of hematopoiesis [1,2]. Thrombocytopenia is a frequent complication in patients with hematological conditions that require HSCT [3]. Recent studies suggest that the current methods used by dentists to treat thrombocytopenic patients are safe and local procedures for hemostasis are sufficient to address any bleeding complications. However, the benefits of platelet transfusion still remain unclear [4,5]. The approach used in thrombocytopenic patients requiring HSCT is still dependent on the experience and judgment of the surgeon as there is limited literature available on the treatment of such cases. The aim of this study was to evaluate the incidence of intraoperative and postoperative complications of dental surgical procedures conducted in patients requiring HSCT.

# **Materials and Methods**

# Study design and sample

The present study was a retrospective analysis in 33patients with hematologic diseases referred for dental extraction to the School of Dentistry at the Universidade Federal de Minas Gerais between 2002 and 2013. All the patients eligible for this study underwent at least one tooth extraction, had complete blood count at the time of consultation, and were prepared for HSCT. Dental extractions were involved in the oral environment stabilization procedures prior to HSCT. In keeping with the institutional protocol, transfusion of platelets was performed in patients with counts less than 50,000/µL.

Platelets were transfused on the same day and few hours prior to the surgical procedure. No prophylactic antibiotic or antiinflammatory drugs were used in any of the patients. The study was conducted in accordance with the declaration of Helsinki and was approved by the University ethical committee.

# Study variables

The following variables were included in the analysis: age, gender, primary disease, platelet count, number of extracted teeth, type of extraction, use of additional local hemostatic measures, leukocyte count, and hemoglobin and hematocrit levels. The primary outcome was postoperative bleeding that required intervention. Intraoperative complications were considered as excessive bleeding and difficult hemostasis using conventional techniques such as local compression and suture. The additional hemostatic measures consisted in the use of absorbable hemostat.

#### Results

The basic clinical information of the subjects given in *Table 1*. From the total of 33 patients, 7 showed platelet count below  $100,000/\mu$ L (*Figure 1*). Patients' blood count prior to dental extraction is on *Table 2*.

None of the patients presented any significant bleeding during or after the surgical procedures. However, fibrillar absorbable sponges were required in two of the cases. Moreover, no infectious complications were observed, despite not using prophylactic antibiotics. Platelet transfusion was indicated in two cases. Eighty-one teeth were extracted comprising 40 molars, 30 premolars, 4 canines, 5 incisors, and 2 deciduous molars. Eight out of the 40 molars were impacted.

### Discussion

Myelosuppressive chemotherapies are frequently used in patients with hematologic malignancies, resulting in immunodeficiency and thrombocytopenia. Dental interventions

Corresponding author: Professor. Ricardo Santiago Gomez, School of Dentistry, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Pampulha - 31270-901, Belo Horizonte, Minas Gerais, Brasil; E-mail: rsgomez@ufmg.br

**Table 1.** Basic descriptive information of subjects included in the study.

Study Variable	Descriptive data	Total
Male/Female	22/10	32
Age (years),	Mean ± SD (range)	$39 \pm 15.2$ (67–12)
Patient Diagnoses	Chronic myeloid leukemia	8
	Acute myeloid leukemia	4
	Multiple myeloma	7
	Acute lymphocytic leukemia	4
	Fanconi anemia	1
	Aplastic anemia	2
	Hodgkin's lymphoma	2
	Myelofibrosis	1
	Immune thrombocytopenic purpura	1
	Myeloid sarcoma	1
	Unspecified leukemia	2
Local measures used, n (%)	Fibrillar absorbable sponge	2

SD: standard deviation




Figure 1. Distribution, mean and standard deviation of platelet count before each clinical session for teeth extraction. Note that ten patients underwent more than one clinical session.

play an important role in the control of dental infections during the phase of chemotherapy and HSCT [6]. Restorative, periodontal and surgical dental procedures are necessary prior to the conditioning regimen for HSCT, thus emphasizing the importance of interdisciplinary treatment for such patients [7,8].

Although normal platelet counts range from 150,000 to  $400,000/\mu L$ , a platelet count of  $100,000/\mu L$  is considered as the cut-off value by some authors for dental extractions [4,5]. However, lower values are acceptable in case of minor procedures [5]. Platelet transfusion is recommended preoperatively when the count is lower than  $50,000/\mu L$  [4]. Invasive surgical procedures such as dental extractions should be performed when there are precise indications, keeping

#### References

- 1. Fonseca MA. Long-term oral and craniofacial complications following pediatric bone marrow transplantation. *Pediatric Dentistry*, 2000; **22**:57-62.
  - 2. AlJohani NI, Thompson K, Hasegawa W, White D, Kew

**Table 2.** Blood counting panel of patients submitted to dental extraction.

Blood component	Mean	Standard deviation	Range
Hemoglobin (g/dL)	12.10	± 3.20	6.40 - 18.00
Hematocrit (%)	36.10	± 10.00	18.50 - 51.50
Erythrocytes (10 <sup>6</sup> /μL)	3.94	± 1.16	2.11 - 624.00
Mean corpuscular volume (fL)	90.74	± 6.02	78.80 – 108.04
Mean corpuscular hemoglobin (pg)	30.49	± 2.26	26.30 – 36.00
Mean corpuscular hemoglobin concentration (g/dL)	25.75	± 14.40	0.32 – 36.70
Leukocytes(10 <sup>3</sup> /μL)	4.82	± 3.00	620 - 14300
Neutrophil (10³/μL)	2.62	± 2.15	0.01 - 8.12
Lymphocyte (10 <sup>3</sup> /μL)	1.60	± 0.94	0.09 - 3.86
Monocyte (10 <sup>3</sup> /μL)	0.49	± 0.34	0.06 - 1.66
Eosinophil (10 <sup>3</sup> /μL)	0.24	± 0.26	0.00 - 0.90
Basophil (10 <sup>3</sup> /μL)	0.043	± 0.05	0.00 - 0.14
Platelet count (10 <sup>3</sup> /μL)	178.70	± 88.7	48.00 – 366.00
International normalized ratio (INR)*	1,06	± 0,69	0.75 – 1.91

<sup>\*</sup>Data available from ten patients.

in mind the systemic condition of the patient. Although prophylactic antibiotics have been recommended in patients with granulocyte count below  $2{,}000/\mu L$  [9,10], this was not validated by evidence based studies. In our institution prophylactic antibiotics are used only in patients with counts less than  $500/\mu L$ .

In the present study, none of the patients received prophylactic antibiotics and no postoperative infection was observed. Moreover, none of the subjects referred from the HSCT unit underwent bleeding complications after tooth extraction. Among the conditions listed in *Table 1*, aplastic anemia is the condition most frequently associated with thrombocytopenia. The low number of patients with aplastic anemia included in our study helps explain the fact that only 6 subjects presented with platelet counts below 100,000/μL. Therefore, the clinical profile of the patients attending our service may have also contributed to the absence of intraoperative or postoperative bleeding complications.

A traumatic surgical techniques and sutures that aid in primary mucosal closurehelp in controlling bleeding and inducing hemostasis and are essential in thrombocytopenic patients [5]. The use of fibrillar absorbable sponges inside the alveolus and plasmin inhibitors such as tranexamic acid and \(\varepsilon\)-aminocaproic acid are measures that help to preserve the clot and promote hemostasis [5,11]. Although we have not used any anti-fibrinolytic agents in the present cohort, fibrillar absorbable sponges were necessary in two of the cases. In conclusion, our data shows that bleeding complications are rare in patients with hematological conditions requiring HSCT and dental extraction procedures are safe.

- A, Couban S. Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience. *Current Oncology*.2014; **21**: 434-440.
- 3. Liebman HA. Thrombocytopenia in cancer patients. *Thrombosis Research*.2014; **133**:63-69.

- 4. Fillmore WJ, Leavitt BD, Arce K. Dental extraction in the thrombocytopenic patient is safe and complications are easily managed. *Journal of Oral Maxillofacial Surgery*.2013; 71:1647-1652
- 5. Henderson JM, Bergman S, Salama A, Koterwas G. Management of the oral and maxillofacial surgery patient with thrombocytopenia. *Journal of Oral Maxillofacial Surgery*.2001; **59**:421-427.
- 6. Akashi M, Shibuya Y, Kusumoto J, Furudoi S, Inui Y, Yakushijin K, Okamura A, Matsuoka H, Komori T. Myelosuppression grading of chemotherapies for hematologic malignancies to facilitate communication between medical and dental staff: Lessons from two cases experienced odontogenic septicemia. *BMC Oral Health*.2013; 19:13-41.
- 7. Elad S, Garfunkel AA, Or R, Michaeli E, Shapira MY, Galili D. Time limitations and the challenge of providing infection-

- preventing dental care to hematopoietic stem-cell transplantation patients. *Supportive Care in Cancer*.2003; **11**:674-677.
- 8. Durey K, Patterson H, Gordon K. Dental assessment prior to stem cell transplant: treatment need and barriers to care. *BritishDental Journal*.2009; **206**: 478-479.
- 9. Majorana A, Schubert MM, Porta F, Ugazio AG, Sapelli PL. Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. *Support Care Cancer*. 2000; **8**:353-365.
- 10. Yamagata K, Onizawa K, Yanagawa T, Takeuchi Y, Hasegawa Y, Chiba S, Bukawa H. Prospective study establishing a management plan for impacted third molar in patients undergoing hematopoietic stem cell transplantation. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology Endodontics*.2011; **111**:146-152.
- 11. Al-Horani RA, Desai UR. Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders. *Medicinal Research Reviews*. 2014.